The knock on the company is going stale: this quarter's own facts cut against the standing doubt
The model's full reasoning — Q1 2022 call → NO我们根据提供的财报电话会议记录,判断是否存在一个明确的、公司特定的疑虑,并且本季度的实际运营证据是否明确反驳了该疑虑。 首先,寻找公司特定的疑虑。在电话会议中,管理层多次提到“capacity constraints”(产能限制),即由于杠杆率限制,BDC不得不拒绝一些投资机会。例如,Stuart Aronson说:“the BDC has turned down 4 origination opportunities during the first quarter due to capacity constraints.” 这暗示投资者可能担心公司无法充分利用其投资能力,或者增长受限。但这是否是一个“standing doubt”?管理层在回答中提到了这一点,但更多是解释他们如何管理杠杆率。另外,关于第二留置权贷款不足的问题,管理层提到“we continue to look to add second lien loans to balance our portfolio but have found few that are within our conservative risk return parameters.” 这可能是一个疑虑:公司过于依赖第一留置权贷款,导致收益率较低,可能影响股息覆盖。但管理层通过提高杠杆率来弥补。然而,这些是否构成“standing doubt”? 更明显的可能是关于Grupo HIMA的损失。管理层承认了这笔损失,并解释了退出原因。但这是本季度发生的事件,不是预先存在的疑虑。另外,关于PlayMonster的重组,管理层提到“we remain optimistic of our ability to generate a strong recovery over time.” 这可能是对过去疑虑的回应。 再仔细看,分析师的问题中,Mickey Schleien问:“given your long track record in the credit markets, I'd really be interested in hearing your outlook for the rest of this year and going into next year in terms of the default environment” 这更多是宏观问题。Bryce Rowe问关于JV的规模,管理层回答有上限。Robert Dodd问关于预付款收入,管理层说预期会减少。 但有没有一个明确的、公司特定的疑虑,比如“这家公司能否持续支付股息”或“其投资组合质量是否恶化”?管理层在电话中多次强调“we are well positioned to continue executing our three-tiered sourcing approach”和“our portfolio as a whole remains very high quality and healthy.” 这可能是对疑虑的回应。 然而,从电话记录看,管理层似乎没有直接回应一个明确的、预先存在的疑虑。分析师的问题更多是询问前景和策略,而不是质疑公司。管理层自己提到“capacity constraints”和“second lien shortage”,但这些更像是运营细节,而非重大疑虑。 再考虑“standing doubt”是否可见。例如,管理层说“we are modestly under our 1.35x limit”和“we expect to continue to run the BDC up to 1.35x leverage in order to help the BDC consistently earn its $0.355 quarterly dividend.” 这暗示投资者可能担心股息覆盖不足,但管理层用实际业绩回应。本季度核心NII为$0.344,低于股息$0.355,但管理层提到有资本利得激励费逆转,且预期未来会改善。但这是否是“current period's own operating evidence”反驳了疑虑?实际上,本季度核心NII低于股息,但管理层说“we are well positioned”等,没有具体事实。 再仔细看,管理层提到“we have already received an additional 3 full repayments totaling $45 million subsequent to quarter end.” 这是实际事件,但这是关于预付款,不是关于疑虑。 或许疑虑是关于“公司能否在竞争激烈的市场中找到足够的高收益投资机会”?管理层说“we have turned down 4 origination opportunities due to capacity constraints”,这实际上表明需求旺盛,但公司因杠杆限制而无法接受,这反而证明了公司有足够机会,但被限制。这可能是对“增长受限”疑虑的回应,但本季度实际部署了$83.6百万,创纪录,这确实反驳了“无法找到投资”的疑虑。 但这是否是“standing doubt”?可能投资者担心公司无法充分利用资本,但管理层用实际部署数据回应。 另一个可能:关于Grupo HIMA的损失,管理层承认了,但说“we recovered approximately 75% of the capital invested”,这可能是对“损失会持续”的疑虑的回应,但这是本季度发生的损失,不是预先存在的。 我认为没有明确的、公司特定的、预先存在的疑虑被分析师或管理层明确提及。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| IFS | Intercorp Financial Services Inc. | Q1 2024 | 2024-05-14 | C+ |
| PRA | ProAssurance Corporation | Q1 2024 | 2024-05-11 | D |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GL | Globe Life Inc. | Q1 2024 | 2024-04-23 | F |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| BXSL | Blackstone Secured Lending Fund | Q1 2023 | 2023-05-10 | A |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| CLSD | Clearside Biomedical, Inc. | Q3 2022 | 2022-11-09 | C |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| EXFY | Expensify, Inc. | Q2 2022 | 2022-08-12 | D |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FARM | Farmer Bros. Co. | Q3 2022 | 2022-05-07 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| STC | Stewart Information Services Corporation | Q1 2022 | 2022-04-29 | C+ |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| GECC | Great Elm Capital Corporation | Q3 2018 | 2018-11-13 | B |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| PII | Polaris Inc. | Q3 2017 | 2017-10-24 | C+ |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| MTG | MGIC Investment Corporation | Q3 2017 | 2017-10-18 | B+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| ULBI | Ultralife Corporation | Q3 2016 | 2016-10-29 | C+ |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
BRX · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible on the call, and if this period's operating evidence cuts against it. YES The standing doubt is the skepticism that tenant disruptions (especially bankruptcies like Bed Bath) will create occupancy pressure and throw markets out of equilibrium, given the recaptured space and potential for more filings. This is visible in analyst questions (Todd Thomas on Bed Bath impact and market equilibrium; others circling back on bad debt 75-110 bps and bankruptcy activity) and management's acknowledgment that "recent retailer bankruptcy announcements will result in occupancy pressure" while noting they've "been preparing for the last several quarters." This period's evidence cuts against it: record 94% total occupancy (up sequentially in a seasonally weak quarter), small-shop at 89.
CME · Q2 2022 → YESThe question is: Identify ONE well-defined DOUBT that has been weighing on the company, and see if the current period's operating evidence moves against that doubt. YES The standing doubt is the perceived risk that the legacy NEX Group businesses (BrokerTec and EBS) would continue to show range-bound revenue and fail to deliver meaningful growth despite a constructive macro backdrop, as directly raised by Alex Blostein. Management engages this concern head-on by recounting concrete operating evidence from 2Q: BrokerTec US treasuries ADV up 14% YoY, US repo up 25% YoY, EU repo up 14% YoY, plus $4.5 billion in new cross-sell volume from previously non-trading clients and record RV trading volumes of $2.4 billion; 90% of the migration to Globex is complete, with the remaining EBS migration also finished and system enhancements underway.
BXSL · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible in the transcript, and if this period's operating evidence moves against it. YES The standing doubt visible in the transcript is the skepticism that BXSL’s credit performance will be materially worse than the broader private-credit market because of its exposure to higher-rate environments and the “tails” of the portfolio (i.e., the small slice of companies whose interest-coverage ratios could fall below 1× when 5 % rates are stress-tested). Management itself flags this concern by noting that “it is less about averages… much more about the tails” and that investors keep asking about the percentage of the portfolio below 1× ICR. This quarter’s operating evidence directly counters that doubt: - 0.